IP Library Granted Patent US 8,163,546
Granted Patent B2
US 8,163,546 · App. 12/748,247 · Granted Apr 24, 2012

Mammalian cell-based immunoglobulin display libraries

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,546
App. No.
12/748,247
Granted
Apr 24, 2012
Kind
B2
Abstract

Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.

Claims (39)

1. A vector for expressing an antibody fragment comprising:

an origin of replication;

a polynucleotide encoding a immunoglobulin constant domain; and, a polynucleotide encoding a cell surface tether domain selected from the group consisting of platelet derived growth factor receptor (PDGF-R) transmembrane domain (SEQ ID NO:4), B7-1 (CD80) transmembrane domain (SEQ ID NO:6), and glycosidylphosphatidylinositol (GPI) signal domain (SEQ ID NO:2),

wherein said polynucleotide encoding a cell surface tether domain is flanked by a first and a second restriction endonuclease recognition site.

2. The vector of claim 1 , wherein said immunoglobulin constant domain comprises a heavy chain constant domain.

3. The vector of claim 2 , wherein said immunoglobulin heavy chain constant domain is selected from the mu constant chain domain, the delta constant chain domain, the gamma constant chain domain, the alpha constant chain domain or the epsilon constant chain domains.

4. The vector of claim 2 , wherein said heavy chain constant domain comprises a hinge, a CH2 domain, and a CH3 domain.

5. The vector of claim 2 , wherein said heavy chain constant domain comprises a hinge.

6. The vector of claim 1 , wherein said immunoglobulin constant domain comprises a light chain constant domain.

7. The vector of claim 6 , wherein said light chain domain is selected from the kappa constant chain domain or the lambda light chain domain.

8. The vector of claim 2 further comprising:

a polynucleotide encoding an immunoglobulin light chain variable domain;

and a polynucleotide encoding an immunoglobulin heavy chain variable domain.

9. The vector of claim 8 , further comprising an internal ribosome entry site.

10. The vector of claim 2 further comprising a polynucleotide encoding a heavy chain variable domain.

11. The vector of claim 8 , wherein said immunoglobulin light chain variable domain and said immunoglobulin heavy chain variable domain is generated from chicken, rabbit, llama, sheep, mouse, rat, hamster, non-human primate, or human.

12. The vector of claim 2 , further comprising a polylinker sequence.

13. The vector of claim 2 , wherein said origin of replication is operative in a eukaryotic cell.

14. The vector of claim 13 , wherein the origin of replication is the EBV OriP sequence.

15. The vector of claim 14 , further comprising a polynucleotide encoding an Epstein-Barr Nuclear Antigen 1 (EBNA-1) protein.

16. The vector of claim 13 , wherein said eukaryotic cell is selected from 293-HEK, HeLa, Jurkat, Raji, Daudi, COS, or CV-1 cells.

17. A vector for expressing an antibody fragment comprising:

an origin of replication;

a first polynucleotide encoding an immunoglobulin light chain constant domain, wherein;

a second polynucleotide encoding an immunoglobulin heavy chain constant domain, wherein said constant domain comprises a CH1 domain and a hinge; and

a polynucleotide encoding a cell surface tether domain selected from the group consisting of platelet derived growth factor receptor (PDGF-R) transmembrane domain (SEQ ID NO:4), B7-1 (CD80) transmembrane domain (SEQ ID NO:6), and glycosidylphosphatidylinositol (GPI) signal domain (SEQ ID NO:2),

wherein said polynucleotide encoding a cell surface tether domain is flanked by a first and a second restriction endonuclease recognition site.

18. The vector of claim 17 further comprising:

a polynucleotide encoding an immunoglobulin light chain variable domain;

and a polynucleotide encoding an immunoglobulin heavy chain variable domain.

19. The vector of claim 17 , further comprising a polylinker sequence.

20. The vector of claim 17 , further comprising an internal ribosome entry site.

21. The vector of claim 18 , wherein said immunoglobulin light chain variable domain and said immunoglobulin heavy chain variable domain is generated from chicken, rabbit, llama, sheep, mouse, rat, hamster, non-human primate, or human.

22. The vector of claim 17 , wherein said immunoglobulin heavy chain constant domain is selected from the delta constant chain domain, the gamma constant chain domain, or the alpha constant chain domain.

23. The vector of claim 17 , wherein said immunoglobulin light chain constant domain is selected from the kappa constant domain or the lambda constant domain.

24. The vector of claim 17 , wherein said origin of replication is operative in a eukaryotic cell.

25. The vector of claim 24 , wherein the origin of replication is the EBV OriP sequence.

26. The vector of claim 25 , further comprising a polynucleotide encoding an Epstein-Barr Nuclear Antigen 1 (EBNA-1) protein.

27. The vector of claim 24 , wherein said eukaryotic cell is selected from 293-HEK, HeLa, Jurkat, Raji, Daudi, COS, or CV-1 cells.

Assignments (2)
CHANGE OF NAME Recorded Feb 18, 2013
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 029825/0070 →
CHANGE OF NAME Recorded Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →